Sepsis is a life-threatening condition characterized by dysregulated host responses to infection, leading to organ dysfunction primarily affecting the lungs, kidneys and capillaries. It can result in severe complications such as Acute Respiratory Distress Syndrome (ARDS), Acute Kidney Injury (AKI), Disseminated Intravascular Coagulation (DIC), which pose significant threats to human life. According to statistics, sepsis-related deaths account for 20% of the total global mortality each year. The diagnosis and treatment of sepsis are highly dependent on various highly specific biomarkers, whose biological activities play a role in the progression of sepsis. Soluble Cluster of Differentiation 14 Subtype (sCD14-ST) is one such biomarker high specificity. Recent studies have found that sCD14-ST holds high clinical value in the early diagnosis, treatment guidance, and prognosis prediction of sepsis and it can serve as an independent predictor of the severity of septic shock and organ dysfunction. This review aims to summarize the research advancements of sCD14 in sepsis, with the goal of providing assistance to sepsis patients